Executives at 2seventy Bio, Inc. were tight-lipped during their second-quarter earnings call about detailed results from the Phase III KarMMa-3 clinical trial of chimeric antigen receptor T-cell (CAR-T) therapy Abecma (idecabtagene vicleucel) in third- to fifth-line multiple myeloma, but the data seem to leave the CAR-T therapy well-positioned to significantly expand its pool of eligible patients. However, the product’s chief competitor – Johnson & Johnson and Legend Biotech Corp.’s Carvykti (ciltacabtagene autoleucel) – may end up extending its reach into an even earlier-line treatment first.
Bristol Myers Squibb Company and 2seventy announced positive top-line results on 10 August from KarMMa-3, the same day that 2seventy announced its second quarter earnings. However, the partners did...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?